First Time Loading...
I

Immuneering Corp
NASDAQ:IMRX

Watchlist Manager
Immuneering Corp
NASDAQ:IMRX
Watchlist
Price: 2.89 USD 18.93% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of IMRX.

Key Points:
IMRX Intrinsic Value
Base Case
Not Available
I
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Immuneering Corp's business.

What risks and challenges
does Immuneering Corp face in the near future?

Summarize the latest earnings report
of Immuneering Corp.

Provide P/E
for Immuneering Corp and its competitors.

Financials

Balance Sheet Decomposition
Immuneering Corp

Current Assets 89.1m
Cash & Short-Term Investments 85.7m
Other Current Assets 3.4m
Non-Current Assets 13.5m
PP&E 5.4m
Intangibles 7.1m
Other Non-Current Assets 1m
Current Liabilities 7.8m
Accounts Payable 2.1m
Accrued Liabilities 5.5m
Other Current Liabilities 259.8k
Non-Current Liabilities 4.2m
Other Non-Current Liabilities 4.2m
Efficiency

Earnings Waterfall
Immuneering Corp

Revenue
0 USD
Operating Expenses
-58.4m USD
Operating Income
-58.4m USD
Other Expenses
4.9m USD
Net Income
-53.5m USD

Free Cash Flow Analysis
Immuneering Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

IMRX Profitability Score
Profitability Due Diligence

Immuneering Corp's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

19/100
Profitability
Score

Immuneering Corp's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

IMRX Solvency Score
Solvency Due Diligence

Immuneering Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Immuneering Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMRX Price Targets Summary
Immuneering Corp

Wall Street analysts forecast IMRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMRX is 15 USD .

Lowest
Price Target
Not Available
Average
Price Target
15 USD
419% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

IMRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

IMRX Price
Immuneering Corp

1M 1M
-53%
6M 6M
-62%
1Y 1Y
-70%
3Y 3Y
-84%
5Y 5Y
-84%
10Y 10Y
-84%
Annual Price Range
2.89
52w Low
1.91
52w High
13.36
Price Metrics
Average Annual Return -39.91%
Standard Deviation of Annual Returns 51.61%
Max Drawdown -94%
Shares Statistics
Market Capitalization 84.6m USD
Shares Outstanding 29 283 300
Percentage of Shares Shorted 17.12%

IMRX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Immuneering Corp

Country

United States of America

Industry

Biotechnology

Market Cap

84.6m USD

Dividend Yield

0%

Description

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. The company is headquartered in Cambridge, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-07-30. The firm is focused on improving patient outcomes by advancing a pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Its development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Its lead product candidate, IMM-1-104, is designed to be a selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The firm's oncology programs target mutations of the RAS/RAF/MEK/ERK, (MAPK) and the PI3K/AKT/mTOR (mTOR), pathways. Its oncology programs include Dual-MEK: IMM-1-104, MEK-io, Trifecta-MEK, KRAS4B, RAS Induction, Covalent-MEK, and PI3K-alpha. The firm's neuroscience pipeline on Alzheimer's Disease (AD). Its neuroscience programs include IMM-ALL-01 and IMM-ALL-03.

Contact

MASSACHUSETTS
Cambridge
245 Main Street, Second Floor
+16175008080.0
https://immuneering.com/

IPO

2021-07-30

Employees

64

Officers

Co-Founder, President, CEO & Director
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Co-Founder & Chair Emeritus
Mr. Robert J. Carpenter M.B.A., M.S.
Chief Scientific Officer
Dr. Brett M. Hall Ph.D.
Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
Ms. Mallory Morales CPA
Director of Accounting & Operations and Assistant Corporate Controller
Ms. Paula George CPA
Chief Legal Officer & Secretary
Mr. Michael D. Bookman J.D.
Show More
Chief People Officer
Ms. Leah R. Neufeld
Head of Discovery & VP
Dr. Peter King Ph.D.
Head of Translational Pharmacology & VP
Dr. Praveen Nair Ph.D.
Chief Business Officer
Mr. Harold E. Brakewood
Show Less

See Also

Discover More